Wolfe Research Has Bearish Forecast for Biogen Q2 Earnings

Biogen Inc. (NASDAQ:BIIB) – Investment analysts at Wolfe Research cut their Q2 2026 earnings estimates for shares of Biogen in a research report issued on Monday, April 20th. Wolfe Research analyst A. Hammond now forecasts that the biotechnology company will post earnings per share of $3.78 for the quarter, down from their previous forecast of $4.32. The consensus estimate for Biogen’s current full-year earnings is $15.75 per share.

Biogen (NASDAQ:BIIB) last announced its earnings results on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, topping the consensus estimate of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s quarterly revenue was down 7.2% on a year-over-year basis. During the same quarter last year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS.

Several other brokerages also recently commented on BIIB. Oppenheimer lifted their target price on shares of Biogen from $250.00 to $275.00 and gave the stock an “outperform” rating in a report on Wednesday, April 1st. Wells Fargo & Company boosted their price objective on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a report on Sunday, February 8th. Rothschild & Co Redburn boosted their price objective on shares of Biogen from $150.00 to $180.00 and gave the stock a “neutral” rating in a report on Wednesday. HSBC boosted their price objective on shares of Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a report on Tuesday, March 17th. Finally, Tudor Pickering set a $201.00 price objective on shares of Biogen in a report on Monday, February 9th. Fourteen equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $211.31.

Biogen Stock Performance

Shares of BIIB opened at $187.88 on Friday. The company has a market capitalization of $27.57 billion, a PE ratio of 21.33, a price-to-earnings-growth ratio of 2.54 and a beta of 0.16. Biogen has a one year low of $115.25 and a one year high of $202.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The company’s fifty day moving average price is $185.37 and its 200 day moving average price is $174.82.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.18% of the company’s stock.

Institutional Trading of Biogen

Institutional investors have recently made changes to their positions in the business. Reflection Asset Management acquired a new stake in shares of Biogen during the 4th quarter valued at about $25,000. WPG Advisers LLC boosted its position in shares of Biogen by 417.9% during the 4th quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock valued at $26,000 after acquiring an additional 117 shares in the last quarter. Accredited Wealth Management LLC boosted its position in shares of Biogen by 1,233.3% during the 3rd quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares in the last quarter. First Horizon Corp acquired a new stake in shares of Biogen during the 4th quarter valued at about $30,000. Finally, WFA of San Diego LLC acquired a new stake in shares of Biogen during the 2nd quarter valued at about $32,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: UBS upgraded BIIB to Buy and raised its price target to $225 (from $185), citing a “slew of pipeline catalysts” over the next 12–15 months that could drive material upside. This is the primary bullish driver supporting higher share prices. Article Title
• Neutral Sentiment: JPMorgan raised its price target on BIIB to $185 (from $175) but kept a Neutral rating — a modest technical upward revision that signals limited near-term conviction despite a higher target. Article Title
• Neutral Sentiment: Rothschild & Co. Redburn raised its price target to $180 (from $150) and published quarterly EPS breakouts (Q1–Q4 2026 estimates), while maintaining a Neutral rating — incremental data for modeling but not a clear buy signal. Article Title
• Neutral Sentiment: Public mentions (e.g., Jim Cramer citing reopened coverage after a Wells Fargo take) add retail visibility but are not a fundamental catalyst; they may boost trading volume without changing earnings trajectory. Article Title
• Negative Sentiment: Wolfe Research cut near-term EPS estimates: Q1 2026 forecast lowered (to $2.64) and Q2 2026 EPS cut materially (to $3.78 from $4.32). Those downgrades reduce near-term earnings visibility and are a key reason for downward pressure.
• Negative Sentiment: HSBC maintains a Reduce rating with a $150 price target and longer-term FY2026–FY2029 EPS projections that imply more caution on valuation and growth — a bearish signal for investors focused on safety and downside protection.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.